Stock comparison
MiMedx Group
ResMed
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
MDXG
MiMedx Group
Market cap
$539.18M
Sector
Healthcare
RMD
ResMed
Market cap
$30.18B
Sector
Healthcare
Overall winner
ResMed RMD
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | MDXG | RMD | Winner |
|---|---|---|---|
| Warren Buffett | 57C | 72B | RMD |
| Benjamin Graham | 50D | 75B | RMD |
| Philip Fisher | 54C | 75B | RMD |
| Peter Lynch | 48D | 58C | RMD |
| Joel Greenblatt | 22F | 47D | RMD |
| Charlie Munger | 44D | 69B | RMD |
| Terry Smith | 51D | 73B | RMD |
Side-by-side metrics
| Metric | MDXG | RMD |
|---|---|---|
| Market cap | $539.18M | $30.18B |
| P/E (TTM) | 17.6x | 19.6x |
| EV/EBIT | 6.0x | 17.1x |
| ROIC (TTM) | 10.81% | 19.63% |
| Gross margin | 81.04% | 61.69% |
| Net margin | 7.88% | 27.44% |
| Revenue CAGR 5y | 14.68% | 12.64% |
| EPS CAGR 5y | - | 30.73% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 1.14% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
MDXG leads on
- Debt / Equity0.0xvs 0.1x+95%
- EV/EBIT6.0xvs 17.1x+65%
- Gross margin81.04%vs 61.69%+24%
- Revenue CAGR 5y14.68%vs 12.64%+14%
RMD leads on
- Dividend yield1.14%vs 0.0%+100%
- Market cap$30.18Bvs $539.18M+98%
- Net margin27.44%vs 7.88%+71%
- ROIC (TTM)19.63%vs 10.81%+45%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.